FDA Approves Merilog: A New Rapid-Acting Insulin Option

The U.S. Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart). 

This means you now have another rapid-acting insulin option to help keep your blood sugar in check at mealtime.

What is Merilog?

• A fast-acting insulin, Merilog is designed to lower blood sugar spikes after eating.
• Works just like Novolog and is taken right before meals (5-10 minutes before).
• Will be available in two forms:
  • 3 mL prefilled pen (for single use)
  • 10 mL vial (for multiple doses)

Why is this a big deal?

• More insulin choices for people with diabetes.
• Biosimilars are often more affordable, making insulin more accessible.
• Same safety and effectiveness as Novolog.

Who Can Use Merilog?

• Adults and children with diabetes who need rapid-acting insulin.
• Anyone already using Novolog can switch with their doctor’s approval. This may be helpful if it is offered at lower cost on your insurance plan or out-of-pocket.

What This Means for You

• Merilog’s approval offers a potentially lower-cost option for the 8.4 million Americans relying on insulin to manage diabetes
• Talk to your doctor or pharmacist to see if Merilog is right for you!